विधियों की तुलना करें

	वैस्कुलिटिस डैमेज इंडेक्स (VDI)	एंकाइलोजिंग स्पॉन्डिलाइटिस रोग गतिविधि सूचकांक (BASDAI)	रोग गतिविधि स्कोर 28-जॉइंट (DAS28)	सिस्टमिक ल्यूपस एरिथेमेटोसस रोग गतिविधि सूचकांक 2000 (SLEDAI-2K)
क्षेत्र	आमवात विज्ञान	आमवात विज्ञान	आमवात विज्ञान	आमवात विज्ञान
परिवार	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
उद्भव वर्ष	2003	1994	1995	2002
प्रवर्तक	Exley et al.	Garrett et al.	Prevoo et al.	Gladman et al.
प्रकार	Clinician-rated	Patient-reported outcome (PRO)	Clinician-rated	Clinician-rated
मौलिक स्रोत	Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
उपनाम	VDI, Vasculitis Permanent Organ Damage Score	BASDAI, BAS-DAI	DAS28, DAS28-CRP, DAS28-ESR	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
संबंधित	4	4	3	3
सारांश	The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.